28.05.2015 19:37:00
|
Moody's: High barriers to entry spur M&A activity in orphan drug sector
New York, May 28, 2015 -- High barriers to entry and high pricing levels of drugs that treat "orphan diseases" will continue to drive acquisition activity in the pharmaceutical sector, says Moody's Investors Service in the report "High Hurdles and High Prices Make Orphan Drugs Appealing M&A Targets."